Clinical trial
Rituximab, Bendamustine and Cytarabine Followed by Venetoclax (V-RBAC) in High-risk Elderly Patients With Mantle Cell Lymphoma (MCL)
NCT03567876 is registered in ClinicalTrials.gov with Fondazione Italiana Linfomi - ETS as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Rituximab, Bendamustine and Cytarabine Followed by Venetoclax (V-RBAC) in High-risk Elderly Patients With Mantle Cell Lymphoma (MCL)
- Lead sponsor
- Fondazione Italiana Linfomi - ETS
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 3, 2018
- Completion date
- October 15, 2025
- Enrollment
- 141 (actual)
- Sites
- 35
Conditions
As the registry lists them; a condition with its own page is linked.